1.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PACB Giù?
Forum
Previsione
Precedente Chiudi:
$1.39
Aprire:
$1.38
Volume 24 ore:
4.66M
Relative Volume:
0.53
Capitalizzazione di mercato:
$426.12M
Reddito:
$188.87M
Utile/perdita netta:
$-400.38M
Rapporto P/E:
-0.9467
EPS:
-1.5
Flusso di cassa netto:
$-260.90M
1 W Prestazione:
-7.79%
1M Prestazione:
-11.25%
6M Prestazione:
-13.41%
1 anno Prestazione:
-8.09%
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Nome
Pacific Biosciences Of California Inc
Settore
Industria
Telefono
650-521-8000
Indirizzo
1305 O'BRIEN DRIVE, MENLO PARK, CA
Confronta PACB con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PACB
Pacific Biosciences Of California Inc
|
1.42 | 417.12M | 188.87M | -400.38M | -260.90M | -1.50 |
![]()
ABT
Abbott Laboratories
|
130.69 | 226.14B | 43.11B | 13.98B | 6.78B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
104.83 | 158.24B | 18.49B | 2.51B | 3.23B | 1.68 |
![]()
SYK
Stryker Corp
|
380.86 | 145.85B | 23.82B | 2.92B | 4.02B | 7.55 |
![]()
MDT
Medtronic Plc
|
89.67 | 114.85B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
79.24 | 46.98B | 5.69B | 4.15B | 623.10M | 6.95 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-11 | Downgrade | UBS | Buy → Neutral |
2024-06-03 | Ripresa | Jefferies | Buy |
2024-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
2024-04-18 | Downgrade | Goldman | Buy → Neutral |
2023-12-14 | Iniziato | Guggenheim | Neutral |
2023-12-14 | Iniziato | Stephens | Overweight |
2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
2023-11-17 | Aggiornamento | UBS | Neutral → Buy |
2023-10-31 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
2023-09-28 | Iniziato | Bernstein | Outperform |
2023-07-05 | Ripresa | JP Morgan | Overweight |
2023-06-30 | Iniziato | Goldman | Buy |
2023-05-10 | Iniziato | Barclays | Equal Weight |
2023-03-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
2023-02-02 | Iniziato | UBS | Neutral |
2023-01-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
2022-01-21 | Ripresa | Cantor Fitzgerald | Overweight |
2022-01-06 | Ripresa | Piper Sandler | Neutral |
2021-10-15 | Ripresa | Cowen | Market Perform |
2021-09-27 | Iniziato | Canaccord Genuity | Buy |
2021-02-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2020-11-03 | Downgrade | Piper Sandler | Overweight → Neutral |
2020-10-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
2020-03-09 | Ripresa | Cantor Fitzgerald | Overweight |
2019-10-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2019-04-02 | Downgrade | Stephens | Overweight → Equal-Weight |
2018-10-19 | Iniziato | Cowen | Outperform |
2017-11-03 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
2017-09-28 | Downgrade | CL King | Buy → Neutral |
2016-11-03 | Reiterato | Cantor Fitzgerald | Buy |
2016-06-27 | Iniziato | CL King | Buy |
2016-04-15 | Iniziato | First Analysis Sec | Overweight |
2016-02-04 | Downgrade | Piper Jaffray | Overweight → Neutral |
2016-01-04 | Reiterato | Cantor Fitzgerald | Buy |
2015-10-23 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2015-08-27 | Iniziato | Cantor Fitzgerald | Buy |
2015-02-04 | Reiterato | Maxim Group | Buy |
2013-09-26 | Reiterato | Maxim Group | Buy |
2013-01-14 | Reiterato | Maxim Group | Buy |
Mostra tutto
Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie
Pacific Biosciences of California Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Will Pacific Biosciences of California Inc. Reverse From Oversold ConditionsChart Driven High Reward Trading Setup Presented - beatles.ru
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
PacBio and Collaborators Release Landmark Platinum Pedigree Dataset, Enhancing Genomic Variant Accuracy by 34% With AI Integration - Quiver Quantitative
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models - Yahoo Finance
How strong is Pacific Biosciences of California Inc. company’s balance sheetGet expert advice on portfolio optimization - Jammu Links News
When is Pacific Biosciences of California Inc. stock expected to show significant growthOutstanding capital returns - Jammu Links News
What catalysts could drive Pacific Biosciences of California Inc. stock higher in 2025Invest smarter with expert trading signals - Jammu Links News
Should I hold or sell Pacific Biosciences of California Inc. stock in 2025Superior risk-adjusted returns - Jammu Links News
How does Pacific Biosciences of California Inc. generate profit in a changing economyAchieve rapid wealth accumulation with smart picks - Jammu Links News
What institutional investors are buying Pacific Biosciences of California Inc. stockUnprecedented profits - Jammu Links News
What are Pacific Biosciences of California Inc. company’s key revenue driversBuild a diversified portfolio for steady growth - Jammu Links News
What is Pacific Biosciences of California Inc. company’s growth strategyExponential return rates - Jammu Links News
Is Pacific Biosciences of California Inc. a growth stock or a value stockAccess high-yield investment alerts now - Jammu Links News
What are analysts’ price targets for Pacific Biosciences of California Inc. in the next 12 monthsLightning-fast growth - Jammu Links News
Published on: 2025-08-03 06:22:09 - Jammu Links News
What is the dividend policy of Pacific Biosciences of California Inc. stockBuild a portfolio that delivers consistent profits - Jammu Links News
How Pacific Biosciences of California Inc. stock performs during market volatilityLow Risk Picks for Daily Trading Released - beatles.ru
Options Data Show Bullish Bias in Pacific Biosciences of California Inc.Conservative Long Term Growth Plans Under Review - metal.it
Does Pacific Biosciences of California Inc. stock perform well during market downturnsFinancial News Target Finder For Smart Trading - jammulinksnews.com
Customer success story: How Dr. Ibrahim Bitar is doubling his research impact while leading the future of European genomics from the Czech Republic - PacBio
Pacific Biosciences (PACB) Jumps 6.5% Ahead of Earnings - MSN
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
What makes Pacific Biosciences of California Inc. stock price move sharplyPattern Breakout Entry Stock Forecast in Focus - metal.it
Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
PacBio, 10x Genomics, QuidelOrtho, STAAR Surgical, and Clover Health Stocks Trade Down, What You Need To Know - Yahoo Finance
Pacific Biosciences Soars 6.5% Pre-Earnings Amid Restructuring Hopes - AInvest
Even after rising 13% this past week, Pacific Biosciences of California (NASDAQ:PACB) shareholders are still down 63% over the past three years - Yahoo Finance
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing - MarketScreener
Is Pacific Biosciences of California (NASDAQ:PACB) A Risky Investment? - simplywall.st
Wyckoff Accumulation Phase Possible in Pacific Biosciences of California Inc.Entry Points For Growing Stocks Identified by Models - metal.it
These 10 Stocks are Winning Big - Insider Monkey
Is it the right time to buy Pacific Biosciences of California Inc. stockBuild a winning investment portfolio - Jammu Links News
Why is Pacific Biosciences of California Inc. stock attracting strong analyst attentionBuild wealth steadily with smart stock selection - jammulinksnews.com
Pacific Biosciences Of California Inc Azioni (PACB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):